Fig. 5.

Treatment with ASOs-loaded RBCEVs suppresses tumor growth by miR-125b knockdown. a Schema of ASOs delivery to nude mice bearing breast cancer xenografts. b Average bioluminescent photon flux of the tumors treated every 3 days with intratumoral injection of 8.25 × 10¹¹ RBCEVs containing NC/125b-ASOs (E-EVs, n = 8 mice) or with 400 pmol NC/125b-ASOs (n = 6 mice), determined using IVIS (mean ± SEM). c Average weight of the mice (mean ± SEM). d Representative images on day 0 and 42. Bioluminescence is shown in pseudocolored radiance. e Representative pictures of the tumors on day 44. f Representative H & E staining images of the tumor and the lung collected on day 44. Scale bar, 50 μm. g miR-125b fold change relative to U6b RNA and NC condition in the tumors after 44 days of treatments, determined using Taqman qRT-PCR (mean ± SEM). P values were determined using one-tail Mann–Whitney test b, g: **P < 0.01; ***P < 0.001; n.s. non-significant. The whole experiment was performed in three independent repeats (three batches of mice)